ArticleScientific reports2025
Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Location- and ADC-based stratification of transition zone PI-RADS 3 lesions to optimize biopsy indication.Abdominal radiology (New York) · 2026Article
- Artificial intelligence-derived transition zone PSA density as a triage tool to reduce unnecessary prostate systematic biopsies in MRI-negative men.Insights into imaging · 2026Article
- Development and validation of a nomogram for predicting clinically significant prostate cancer using serologic indices, multiparametric magnetic resonance imaging, and sound touch elastography parameters: a retrospective study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We intended to investigate the potential of several transitional zone (TZ) volume-related variables for the detection of clinically significant prostate cancer (csPCa) among lesions scored as Prostate Imaging Reporting and Data System (PI-RADS) category 3. Between September 2018 and August 2023, patients who underwent mpMRI examination and scored as PI-RADS 3 were queried from our institution. The diagnostic performances of prostate-specific antigen density (PSAD), TZ-adjusted PSAD (TZPSAD), and TZ-ratio (TZ volume/whole gland prostate volume) were analyzed. We calculated the sensitivity and specificity for each variable, the overall accuracy was evaluated with the area under the receiver operating characteristic curve (AUC). The best cutoff value was determined by the Youden index, and differences between diagnostic performances were compared with the Delong test. A total of 154 TZ lesions were included, of them 28 were diagnosed with csPCa. The AUC for PSAD, TZPSAD, and TZ-ratio were 0.644 (95% CI 0.538-0.751), 0.714 (95% CI 0.607-0.821), and 0.746 (95% CI 0.636-0.856), with corresponding optimal cutoff values of 0.11 ng/ml/ml, 0.21 ng/ml/ml, and 0.66 ng/ml/ml, respectively. PSAD was significantly inferior to either TZPSAD (P = 0.03) or TZ-ratio (P = 0.03). The combination model including TZPSAD, TZ-ratio, and age generated an AUC of 0.838 (95% CI 0.759-0.917), significantly higher than use of these variables alone, with P values of 0.001 and 0.035 for the TZPSAD and TZ-ratio, respectively. TZPSAD and TZ-ratio were found to be independent predictors for differentiating csPCa among TZ lesions categorized as PI-RADS score 3. Furthermore, by combining these two variables with others, the diagnostic performance can be improved significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.